A multicenter randomized Phase III trial of enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer
Phase 3
- Conditions
- castration-resistant prostate cancer
- Registration Number
- JPRN-UMIN000015529
- Lead Sponsor
- Kanazawa University Graduate School of Medical Science, Department of Integrative Cancer Therapy and Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 203
Inclusion Criteria
Not provided
Exclusion Criteria
1. Allergy for enzalutamide, abiraterone, and prednisolone 2. Desire to bear children 3. Patients who were judged unfit for enrollment by physicians in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to PSA progression; TTPP
- Secondary Outcome Measures
Name Time Method Overall survival, radiographic progression-free survival, time to cytotoxic chemotherapy initiation, time to stage-up of ECOG performance status, time to opioid analgesic initiation, PSA response rate